Citations

Mayo Clinic

Showing 10 of 108522 citations.

VTE Rate in Transgender Surgery: Is it Safe to Continue Estrogen?
Pazelli, Alexandre Meira, Shehab, Abdallah A. , Hussein, Sara , Akpala, Christeebella O. , Bite, Uldis, Sharaf, Basel

Plastic and Reconstructive Surgery - Global Open | September 18, 2024 | Volume: 12 | Issue: S8 | Pages: 20-21

10.1097/01.gox.0001063916.79215.96 Get It

Mapping Mandibular Aging in the White Population: AI-Enhanced Shape Analysis of the Lower Facial Third Bony Changes Based on 3D CT Scans of 280 Patients
Hussein, Sara , Rames, Jess D. , Shehab, Abdallah A. , Pazelli, Alexandre Meira, Sears, Victoria A. , Wentworth, Adam, Morris, Jonathan M. , Sharaf, Basel

Plastic and Reconstructive Surgery - Global Open | September 18, 2024 | Volume: 12 | Issue: S8 | Pages: 35-36

10.1097/01.gox.0001063996.46231.58 Get It

The importance of autologous stem cell transplantation in improving outcomes in newly diagnosed patients with multiple myeloma
Gertz, Morie A. , Gertz, Morie A

American Journal of Hematology | September 18, 2024 | Volume: 99 | Issue: 11 | Pages: 2060-2062

10.1002/ajh.27483 | PMID 39291811 Get It

An Update on the Survival of the First 50 Face Transplants Worldwide
Homsy, Pauliina , Barret, Juan P. , Borsuk, Daniel E., Bula, Daniel , Infante-Cossío, Pedro , Lantieri, Laurent , Morelon, Emmanuel, Nasır, Serdar , Papay, Francis , Rodriguez, Eduardo D. , Özkan, Özlenen , Özmen, Selahattin, Huelsboemer, Lioba Franziska , Blondeel, Phillip Nicholas , Gelb, Bruce E. , Mardini, Samir , Morélon, Emmanuel , Petruzzo, Palmina , Pomahač, Bohdan , Lassus, Patrik

JAMA Surgery | September 18, 2024 | Volume: 159 | Issue: 12 | Pages: 1339

10.1001/jamasurg.2024.3748 | PMID 39292472 Get It

Importance Since 2005, a total of 50 face transplants have been reported from 18 centers in 11 countries. The overall survival of the grafts has not yet been established. Objective To assess the survival of the face transplant grafts and evaluate factors potentially influencing it. Design, Setting, and Participants Data on all the transplants included in this multicenter cohort study were collected at participating transplant centers for updated nonpublished data, supplemented with literature review for nonparticipating centers. Data from 2005 until September 2023, were included. Data were analyzed from November 11, 2005, through September 18, 2023. Patients included the first 50 patients in the world to have received a face transplant. Exposure Face transplant graft. Main Outcomes and Measures The primary outcome was the overall survival of the face transplant graft, defined as either transplant loss or patient death. The secondary outcome was the number of acute rejection episodes per year. Results The 50 transplants were performed on 39 men (81%) and 9 women (19%) with a median age of 35 (range, 19-68) years at the time of the transplant. The median follow-up time was 8.9 (range, 0.2-16.7) years. During the follow-up, 6 transplants were lost with 2 patients retransplanted. There were 10 patients who died, 2 of whom had lost a transplant. The 5- and 10-year survival of the transplants was 85% (SD, 5%) and 74% (SD, 7%), respectively. The sequential number of the transplant in the world was a significant predictor of survival (hazard ratio, 95; 95% CI, 90-100; P < 05). The median number of acute rejection episodes per year was 1.2 (range, 0-5.3) for the transplants that were lost and 0.7 (range, 0-4.6) for the transplants that survived. No correlation with patient and transplant variables was detected for either the transplant survival or the number of rejection episodes. Conclusions and Relevance In this study, the overall survival of the face transplants is encouraging. These data suggest that the acceptable long-term survival of face transplants makes them a reconstructive option for extensive facial defects.
Single-Plane Versus Synchronous Biplane Ultrasound Imaging During Vascular Access Procedures: Which Is Better and How Can We Improve?
Anderson, Robert J., Daxon, Benjamin T. , Merren, Michael P.

Journal of the Association for Vascular Access | September 18, 2024 | Volume: 29 | Issue: 3 | Pages: 42-47

10.2309/java-d-24-00005 Get It

Highlights Biplane ultrasound imaging reduces need for probe manipulation during procedure. Providers note clinical benefit of biplane ultrasound imaging for vascular access. Biplane disadvantages include probe size, imaging quality, size of the screen. Thorough didactic and practical education is essential for biplane success. Abstract Background: Use of ultrasound guidance for vascular access procedures is commonplace in inpatient and outpatient care settings. Standard ultrasound probes offer the operator a single-plane view, necessitating rotation of probe to attain dual complimentary views. This mechanical probe rotation increases technical difficulty of ultrasound use. The purpose of this study is to evaluate the rate of cannulation success and efficiency of a synchronous biplane ultrasound mode in ultrasound-guided arterial line placement as compared with a standard single-view ultrasound mode in the operating room setting. Methods: Patients scheduled for elective surgery in which a radial arterial catheter would be used for hemodynamic monitoring were approached for consent to this study. Patients were randomized to either undergo placement with single-plane view versus synchronous biplane view; outcomes were recorded. Providers were provided preprocedural ultrasound education as well as the option of a short hands-on experience; their level of experience was noted. Results: Placement time of a peripheral arterial catheter was longer and required more attempts to be successful using synchronous biplane imaging as compared with single-plane imaging across providers of all skill/experience levels. Subjectively, providers noted the benefit of synchronous biplane imaging in vascular access; however, disadvantages including probe size, quality of imaging, and size of the screen were noted. Discussion: Thorough education regarding the use and functionality of biplane synchronous imaging in vascular access is essential. Additional guided-practice time with experienced operators could also be helpful to overcome the challenges observed in this study.
Dementia risk reduction between DOACs and VKAs in AF: A systematic review and meta‐analysis
Prasitlumkum, Narut , Cooley, Ryan, Bunch, T. Jared , Navaravong, Leenhapong , Prasitlumkum, Narut , Navaravong, Leenhapong , Chokesuwattanaskul, Anthipa , Chokesuwattanaskul, Ronpichai

Journal of Arrhythmia | September 18, 2024 | Volume: 40 | Issue: 5 | Pages: 1115-1125

10.1002/joa3.13142 | PMID 39416243 Get It

AbstractIntroductionDirect oral anticoagulants (DOACs) become the recommended treatment over vitamin K antagonists (VKA) in patients with non‐valvular atrial fibrillation (AF). However, their effectiveness in reducing cognitive impairment and dementia compared to VKA remains unclear.MethodsA systematic literature search was conducted on Ovid MEDLINE, EMBASE, and Cochrane Database. Randomized controlled trials, cohort, or case–control study that assessed incident dementia between AF patients who received DOAC compared to VKA were selected. Relevant study characteristics and the number of incident dementia diagnosis or hazard ratios (HRs) for incident dementia and each dementia subtypes were extracted. Random‐effects model was used to perform meta‐analysis. Standardized mean differences (SMDs) were used to estimate effect sizes for continuous data.ResultsTwelve cohort studies comprising 1 451 069 individuals were included. The incidence of dementia was lower in AF patients prescribed DOACs compared to VKA (HR 0.88, 95% CI 0.83–0.93, I 2 = 61.2%). A lower incident dementia in DOACs group relative to VKA was significantly observed in those less than 75 years of age (< 65 years, HR 0.83 (95% CI 0.72–0.97, I 2 = 0%); 65–74 years, HR 0.86 (95% CI 0.81–0.92, I 2 = 55.4%); and ≥ 75 years, HR 1.07 (95% CI 0.74–1.55, I 2 = 92.5%)) and for the subgroup of patients with vascular dementia (HR 0.91, 95% CI 0.824–0.997, I 2 = 0%).ConclusionsThis meta‐analysis reveals a reduction in incidence of dementia in AF patients prescribed DOACs compared to VKA, particularly in those less than 75 years old and in the vascular dementia subtype.
Infantile hemangioma precursor lesions on day of life 1: A Mayo Clinic retrospective case series
Jing, Frank Z. , Villalpando, Beija K., Tollefson, Megha M. , Jing, Frank Z , Villalpando, Beija K.

Pediatric Dermatology | September 18, 2024 | Volume: 41 | Issue: 6 | Pages: 1053-1056

10.1111/pde.15616 | PMID 39290160 Get It

AbstractBackgroundInfantile hemangiomas (IHs), the most prevalent vascular tumors in infancy, are generally understood to be absent at birth, appearing in the initial weeks of life during their proliferative stage. While the classic presentation is recognizable, the precursor lesion of IHs may be misinterpreted as other entities, including vascular malformations.MethodsA retrospective, single‐center study was conducted, examining neonates with photographed IH precursor lesions on day of life (DOL) 1 and matured classical IHs. The study spanned from 2017 to 2023.ResultsThe case series is comprised of nine neonates all exhibiting precursor lesions on DOL 1. A comparative display of photographs featuring precursor lesions and classic IH is presented. Further tabulated information for each case includes IH locations, subsequent treatment modalities, and further diagnostic workup if necessary.ConclusionsImproving recognition of precursor lesions increases diagnostic accuracy, decreasing unnecessary workup. This, in turn, allows dermatologists to confidently employ close follow‐up management strategies. Additionally, in cases of extensive involvement, recognition of the precursor lesion allows for expedited investigation for syndromes such as PHACE (posterior fossa malformations, hemangioma, arterial anomalies, coarctation of the aorta/cardiac defects, and eye abnormalities) and LUMBAR (lower body IH, urogential anomalies, ulceration, myelopathy, bony deformities, anorectal malformations, arterial anomalies, and renal anomalies).
Characteristics, clinical outcomes, and prognostic factors of colorectal cancer in patients with Crohn’s disease: American versus Korean tertiary referral center perspectives
Suttichaimongkol, Tanita , Hwang, Sung Wook , Kisiel, John B. , Yang, Suk‐Kyun , Park, Sang Hyoung , Kisiel, John B , Yang, Suk-Kyun , Park, Sang Hyoung , Coelho–Prabhu, Nayantara , Ye, Byong Duk , Loftus, Edward V.

Therapeutic Advances in Gastroenterology | September 18, 2024 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/17562848241275342 | PMID 39314760 Get It

Background:Crohn’s disease (CD) exhibits variability in colorectal cancer (CRC) incidence and prognostic factors due to diverse clinical and behavioral characteristics, presenting inconsistencies between Western and Eastern patients.Objectives:This study compared clinical characteristics between CD patients with CRC from the US and Korean tertiary referral centers and defined the prognostic factors related to mortality.Design:Retrospective study.Methods:We reviewed the electronic medical records of 236 adult CD patients with colorectal adenocarcinoma evaluated at Mayo Clinic Rochester, Florida, or Arizona ( N = 200) and Asan Medical Center in Korea ( N = 36) between January 1989 and August 2022.Results:Asan patients had a younger age, shorter CD duration, more colonic involvement (L2 plus L3), penetrating behavior, perianal fistula, and shorter biological treatment duration before CRC diagnosis than Mayo patients. Furthermore, despite significant differences in body mass index, smoking status, primary sclerosing cholangitis, immunomodulators, CRC diagnosis period, clinical presentation, CRC location, surgery, and some histopathological details between the two groups, overall survival was not statistically different ( p value, 0.29, log-rank test). Advanced age (adjusted hazard ratio (aHR), 1.03 per year; 95% confidence interval (CI), 1.01–1.04; p value, <0.01), unresectable CRC (aHR, 5.02; 95% CI, 2.49–10.12; p value, <0.01), and advanced CRC stage (aHR, 1.45 per stage; 95% CI, 1.07–1.97; p value, 0.02) were significantly associated with increased risk of death. CD remission at CRC diagnosis (aHR, 0.26; 95% CI, 0.08–0.91; p value, 0.04), CRC diagnosis period of 2011–2022 (aHR relative to 1989–2000, 0.46; 95% CI, 0.25–0.87; p value, 0.02), and CRC diagnosis by surveillance (aHR, 0.56; 95% CI, 0.32–0.98; p value, 0.04) were significantly associated with decreased risk of death.Conclusion:Notably, some clinical features of CD with CRC differed between Asan and Mayo patients; however, overall survival was not different. CD remission, CRC surveillance, and more recent diagnosis of CRC were associated with a reduced risk of death.